Cover Image
市場調查報告書

類鴉片物質治療藥的產品、開發平台分析和藥物輸送市場

A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market

出版商 Frost & Sullivan 商品編碼 325468
出版日期 內容資訊 英文 75 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
類鴉片物質治療藥的產品、開發平台分析和藥物輸送市場 A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market
出版日期: 2015年03月02日 內容資訊: 英文 75 Pages
簡介

在類鴉片物質治療藥的藥物研發、臨床實驗領域,現在活用了TRF (Tamper Resistant Formulation:防篡改技術) 的製劑手法和處方藥正逐漸普及。

本報告提供全球的類鴉片物質治療藥市場相關分析、主要的治療藥的目前臨床實驗進展 (特別是第三階段) ,及醫藥品市場競爭狀態、各種醫藥品的今後收益額預測等調查、考察。

第1章 調查手法及分析範圍

第2章 摘要整理

第3章 簡介

  • 簡介
  • 類鴉片物質療法相關醫生的指南:中度∼重度的慢性疼痛
  • 類鴉片物質療法相關醫生的指南:神經性疼痛
  • 類鴉片物質療法相關醫生的指南:癌症誘發性疼痛
  • 類鴉片物質療法相關醫生的指南:急性/手術後疼痛

第4章 美國的類鴉片物質治療藥市場概要

  • 簡介 - 慢性疼痛的盛行率:各重症度
  • 類鴉片物質疼痛市場:各地區
  • 美國的類鴉片物質治療藥市場上佔有率第一產品
  • 類鴉片物質治療藥:疼痛的各種類的銷售額佔有率
  • 類鴉片物質治療藥:疼痛用製劑處方藥的銷售額
  • 類鴉片物質治療藥:TRF (防篡改) 及非TRF處方藥的銷售額
  • 類鴉片物質治療藥:各給藥途徑的推算最大銷售額
  • 類鴉片物質治療藥:疼痛貼片產品
  • 改變市場流程的策略
  • 值得注意的企業

第5章 競爭情形

  • 類鴉片物質治療藥市場:競爭情形
  • 已上市產品概要:中度∼重度的慢性疼痛用類鴉片物質治療藥市場
  • 開發平台分析:中度∼重度的慢性疼痛用類鴉片物質治療藥市場
  • 已上市產品:神經性疼痛用類鴉片物質治療藥
  • 開發平台分析:神經性疼痛用類鴉片物質治療藥
  • 已上市產品概要:癌症誘發性疼痛用類鴉片物質治療藥
  • 開發平台分析:癌症誘發性疼痛用類鴉片物質治療藥
  • 已上市產品概要:術後/急性疼痛用類鴉片物質治療藥
  • 開發平台分析:術後/急性疼痛用類鴉片物質治療藥
  • 中度∼重度慢性疼痛的臨床試驗設計比較:第三階段
  • 癌症誘發性疼痛的臨床試驗設計比較:第三階段
  • 術後/急性疼痛的臨床試驗設計比較:第三階段

第6章 今後的產品開發、上市時期預測

  • 美國的產品上市時期的預期
  • 上市前的產品臨床實驗計劃:Remoxy、HYD Tablets
  • 開發中產品的第三階段臨床實驗研究:BEMA Buprenorphine、COL-003、Nucynta
  • 開發中產品的第三階段臨床實驗研究:Zalviso

第7章 臨床實驗後期階段的產品開發動態即時看板系統

  • 產品開發動態即時看板系統:Remoxy (Durect/Pain Therapeutics)
  • 產品開發動態即時看板系統:BEMA Buprenorphine (Endo Pharmaceuticals/Biodelivery)
  • 產品開發動態即時看板系統:HYD Tablet (Purdue Pharma)
  • 產品開發動態即時看板系統:COL-003/Oxycodone DETERx (Collegium)
  • 產品開發動態即時看板系統:緩釋性Nucynta (Grunenthal/J&J)
  • 產品開發動態即時看板系統:快速釋放MoxDuo (Actavis/QRxPharma)

第8章 彙整

第9章 關於FROST & SULLIVAN

目錄
Product Code: NED9-01-00-00-00

Increasing Regulation Push for Tamper-resistant Drugs Driving New Generation of Opioids

This market insight provides data for the Global Opioid Therapeutics market. The analysis looks at opioid pharmaceutical pipeline drugs currently in the market and drugs that are in Phase III stage, which pose a potential threat to competitors. It also offers a competitive analysis of the drugs, and the forecast outcome and impact of each of these drugs. Opioid drugs in the current market have a space for tamper-resistant formulations. The opioids market is segmented into relapsing neuropathic pain, acute and post-operative pain, cancer-induced pain, and moderate to severe chronic pain.

Table of Contents

1. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope

2. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary
  • 2. Executive Summary (continued)
  • 3. Executive Summary (continued)
  • 4. Executive Summary (continued)
  • 5. Executive Summary (continued)
  • 6. Executive Summary (continued)
  • 7. Executive Summary (continued)

3. INTRODUCTION

Introduction

  • 1. Introduction
  • 2. Physician Guidelines to Opioid Therapy-Moderate to Severe Chronic Pain
  • 3. Physician Guidelines to Opioid Therapy-Neuropathic Pain
  • 4. Physician Guidelines to Opioid Therapy-Cancer-induced Pain
  • 5. Physician Guidelines to Opioid Therapy-Acute and Post-operative Pain

4. US OPIOID THERAPEUTICS MARKET OVERVIEW

US Opioid Therapeutics Market Overview

  • 1. Introduction-Chronic Pain Prevalence by Severity
  • 2. Opioid Pain Market by Region
  • 3. Top-selling Products in the US Opioid Therapeutics Market
  • 4. Opioid Therapeutics-Percent Sales by Type of Pain
  • 5. Opioid Therapeutics-Pain Formulation Prescription Sales
  • 6. Opioid Therapeutics-TRF and Non-TRF Prescription Sales
  • 7. Opioid Therapeutics-Estimated Peak Sales by Route of Administration
  • 8. Opioid Therapeutics Market-Pain Patch Products
  • 9. Game-changing Strategies
  • 10. Companies to Watch

5. COMPETITIVE LANDSCAPE

Competitive Landscape

  • 1. Opioid Therapeutics Market-Competitive Landscape
  • 2. Marketed Product Synopsis-Moderate to Severe Chronic Pain Opioid Therapeutics Market
  • 3. Marketed Product Synopsis-Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)
  • 4. Marketed Product Synopsis-Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)
  • 5. Marketed Product Synopsis-Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)
  • 6. Marketed Product Synopsis-Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)
  • 7. Pipeline Analysis-Moderate to Severe Chronic Pain Opioid Therapeutics
  • 8. Pipeline Analysis-Moderate to Severe Chronic Pain Opioid Therapeutics (continued)
  • 9. Pipeline Analysis-Moderate to Severe Chronic Pain Opioid Therapeutics (continued)
  • 10. Marketed Product-Neuropathic Pain Opioid Therapeutics
  • 11. Pipeline Analysis-Neuropathic Pain Opioid Therapeutics
  • 12. Pipeline Analysis-Neuropathic Pain Opioid Therapeutics (continued)
  • 13. Marketed Product Synopsis-Cancer-induced Pain Opioid Therapeutics
  • 14. Marketed Product Synopsis-Cancer-induced Pain Opioid Therapeutics (continued)
  • 15. Pipeline Analysis-Cancer-induced Pain Opioid Therapeutics
  • 16. Marketed Product Synopsis-Post-operative and Acute Pain Opioid Therapeutics
  • 17. Pipeline Analysis-Post-operative and Acute Pain Opioid Therapeutics
  • 18. Moderate to Severe Chronic Pain Clinical Trial Design Comparison-Phase 3
  • 19. Moderate to Severe Chronic Pain Clinical Trial Design Comparison-Phase 3 (continued)
  • 20. Moderate to Severe Chronic Pain Clinical Trial Design Comparison-Phase 3 (continued)
  • 21. Cancer-induced Pain Clinical Development Synopsis-Phase 3
  • 22. Post-operative and Acute Pain Clinical Trial Design Comparison-Phase 3

6. TIMELINE TRANSPARENCY

Timeline Transparency

  • 1. Estimated US Product Launch Timeline
  • 2. Pre-launch Products Clinical Program-Remoxy and HYD Tablets
  • 3. Pipeline Products Clinical Phase 3 Studies-BEMA Buprenorphine, COL-003, Nucynta
  • 4. Pipeline Products Clinical Phase 3 Studies-Zalviso

7. LATE-STAGE DEVELOPMENT-PRODUCT DASHBOARDS

Late-stage Development-Product Dashboards

  • 1. Product Dashboard: Remoxy (Durect/Pain Therapeutics)
  • 2. Product Dashboard: BEMA Buprenorphine (Endo Pharmaceuticals/Biodelivery)
  • 3. Product Dashboard: HYD Tablet (Purdue Pharma)
  • 4. Product Dashboard: COL-003/Oxycodone DETERx (Collegium)
  • 5. Product Dashboard: Nucynta Extended Release (Grünenthal/J&J)
  • 6. Product Dashboard: MoxDuo Immediate Release (Actavis/QRxPharma)

8. THE LAST WORD

The Last Word

  • 1. The Last Word
  • 2. Legal Disclaimer

9. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top